Calcium antagonist: Elgodipine was developed on the base of its coronary selectivity and the relative absence of cardiac effects.

Status: Preclinical Pharmacology and toxicology: completed
Phase I: completed
Phase II: as antianginal (i.v. and oral administration) and as anti-ischemic (i.c. in PTCAs) completed.
Phase III: intravenous and intracoronary formulation for PTCAs are currently under clinical research.

Elgodipine has been licenced to DELAGRANGE (Synthélabo) and to ALMIRALL/PRODESFARMA Group.
Intravenous formulation was expected to reach the market in 1998. This project was arrested in 1999